Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has announced that its self-developed MEK1/2 selective inhibitor, Luvometinib Tablets, has entered Phase 3 clinical trials in China for the treatment of pediatric low-grade glioma (pLGG). This development marks a significant milestone as it is the first MEK-targeted drug in China to reach this stage for this indication. Luvometinib has already been approved for marketing in China for two indications, including the treatment of adult patients with Langerhans cell histiocytosis and pediatric patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas. The drug has also been granted breakthrough therapy designation for additional indications, underscoring Fosun Pharma's commitment to advancing innovative treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.